96 results on '"Currier, Judith S"'
Search Results
2. Systemic inflammation in pregnant women with HIV: relationship with HIV treatment regimen and preterm delivery.
3. Hepatitis B virus clinical and virologic characteristics in an HIV perinatal transmission study in sub-Saharan Africa.
4. Comparison of Antiretroviral Therapies in Pregnant Women Living With Human Immunodeficiency Virus and Hepatitis B Virus: A Randomized Controlled Trial.
5. Trans women have worse cardiovascular biomarker profiles than cisgender men independent of hormone use and HIV serostatus.
6. Brief Report: Impact of Antiretroviral Regimen on Pregnancy and Infant Outcomes in Women With HIV/ HBV Coinfection.
7. Machine Learning Algorithms Using Routinely Collected Data Do Not Adequately Predict Viremia to Inform Targeted Services in Postpartum Women Living With HIV.
8. Poorer Muscle Quality and Quantity With ART Initiation Is Associated With Greater Inflammation and Immune Activation.
9. Impact of ART on Maternal Health After Cessation of Breastfeeding.
10. Maternal HBV Viremia and Association With Adverse Infant Outcomes in Women Living With HIV and HBV.
11. Effects of HIV Infection on Arterial Endothelial Function: Results From a Large Pooled Cohort Analysis.
12. Methotrexate Decreases Tenofovir Exposure in Antiretroviral-Suppressed Individuals Living With HIV.
13. Comparison of guidelines for HIV viral load monitoring among pregnant and breastfeeding women in sub-Saharan Africa.
14. Predictors of Viremia in Postpartum Women on Antiretroviral Therapy.
15. Time to viral rebound and safety after antiretroviral treatment interruption in postpartum women compared with men.
16. Tenofovir concentrations in hair strongly predict virologic suppression in breastfeeding women.
17. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association.
18. Brachial Artery Echogenicity and Grayscale Texture Changes in HIV-Infected Individuals Receiving Low-Dose Methotrexate: AIDS Clinical Trials Group Study A5314.
19. Antiretroviral initiation is associated with increased skeletal muscle area and fat content.
20. Predictors of Impaired HDL Function in HIV-1 Infected Compared to Uninfected Individuals.
21. Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection.
22. Sex-Related Differences in Inflammatory and Immune Activation Markers Before and After Combined Antiretroviral Therapy Initiation.
23. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
24. Birth Outcomes for Pregnant Women With HIV Using Tenofovir-Emtricitabine.
25. A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness.
26. Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks.
27. Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.
28. Proteinuria is Associated With Neurocognitive Impairment in Antiretroviral Therapy Treated HIV-Infected Individuals.
29. Biomarkers From Late Pregnancy to 6 Weeks Postpartum in HIV-Infected Women Who Continue Versus Discontinue Antiretroviral Therapy After Delivery.
30. Body Composition, Soluble Markers of Inflammation, and Bone Mineral Density in Antiretroviral Therapy-Naive HIV-1-Infected Individuals.
31. Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection.
32. Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort.
33. Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women.
34. Safety and Efficacy of Initiating Highly Active Antiretroviral Therapy in an Integrated Antenatal and HIV Clinic in Johannesburg, South Africa.
35. State of the Science Conference Initiative to Decrease Cardiovascular Risk and Increase Quality of Care for Patients Living With HIV/AIDS.
36. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary.
37. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure.
38. Coronary Heart Disease in HIV-Infected Individuals.
39. Management of Metabolic Complications Associated With Antiretroviral Therapy for HIV-1 Infection: Recommendations of an International AIDS Society-USA Panel.
40. Cardiovascular Risk Associated With HIV Therapy.
41. Health values of patients infected with human immunodeficiency virus. Relationship to mental health and physical functioning.
42. Absence of virological changes after acute febrile illnesses in two patients with undetectable pre-illness plasma HIV-1-RNA levels.
43. Abstract 10607: Effects of Low-Dose Methotrexate on Brachial Artery Echogenicity and Grayscale Texture in HIV-Infected Individuals at Increased Cardiovascular Disease Risk: AIDS Clinical Trials Group Study A5314.
44. Soluble levels of receptor for advanced glycation endproducts and dysfunctional high-density lipoprotein in persons infected with human immunodeficiency virus: ACTG NWCS332.
45. Guidelines for managing cardiovascular risk: an evolving area.
46. Introduction.
47. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy.
48. Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229.
49. Associations of antiretroviral drug use and HIV-specific risk factors with carotid intima-media thickness.
50. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.